Replies to post #5471 on Algernon Pharmaceuticals Inc (AGNPF)

[Money $hot]

Algernon Pharmaceuticals Key Research Milestone Summary

Annual Information Form

For The Financial Year Ended August 31, 2018

April 11, 2019

Page 28

1. November 1, 2018 – Company Announces Positive Pre-Clinical Results Showing Lead Compound NP-160 Significantly Reduces NALFD Score and Fibrosis in Non-Alcoholic Fatty Liver Disease.
2. November 5th, 2018 - The Company announced that it amended its research agreement with the University of Florida’s Analytical Chemistry Department to finalize development of the FAIMS working prototype device.
3. November 13, 2018 - Company Announces Positive Pre-Clinical Results For Its Lead Compound NP-178 in Inflammatory Bowel Disease.
4. November 19, 2018 - Company Announces Positive Pre-Clinical Results For Its Lead Compound NP-135 in Chronic Kidney Disease.
5. December 3, 2018 – Company Announces Positive Pre-Clinical Results For Its Lead Compound NP-178 in a New Study for Crohn’s Disease.
6. January 14, 2019 – Company Announces Positive Pre-Clinical Results From a Second Study for Chronic Kidney Disease as well as two Additional Lead Targets.
7. January 21, 2019 – Company Announces 84% Reduction of Fibrosis by Additional Lead Compound In Second Pre-Clinical Study For Non-Alcoholic Fatty Liver Disease.
8. February 25, 2019 – Company Expands Its Research Program to Include Idiopathic Pulmonary Fibrosis.

https://webfiles.thecse.com/sedar_filings/00037722/1904160953176150.pdf

/////AMG